Literature DB >> 26847389

The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months.

Matthew A Lunning1, Jocelyn C Migliacci2, Patrick Hilden3, Sean M Devlin3, Hugo Castro-Malaspina2,4, Sergio Giralt2,4, Miguel-Angel Perales2,4, Andrew D Zelenetz2,4, Craig H Moskowitz2,4, Craig S Sauter2,4.   

Abstract

Early relapsed or refractory follicular lymphoma (FL) warrants consolidation with transplantation, though graft source modality remains controversial. We analysed the outcomes of 44 patients transplanted with either autologous or allogeneic graft sources in the post-rituximab era. No difference in event-free (EFS) or overall survival (OS) was observed between allogeneic (81% and 81%) and autologous transplantation (64% and 70%) at 3 years. There was a significant difference in EFS between allogeneic and autologous transplantation patients with previous remission duration of ≤12 months (80% and 42% at 3 years, P < 0·015). Very early relapsed FL may warrant consideration of allogeneic over autologous transplantation in the appropriate setting.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  follicular lymphoma; non-Hodgkin lymphoma; stem cell transplantation

Mesh：

Year:  2016        PMID： 26847389      PMCID： PMC5051568          DOI： 10.1111/bjh.13947

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  15 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.

Authors:  Marcie R Tomblyn; Marian Ewell; Christopher Bredeson; Brad S Kahl; Stacey A Goodman; Mary M Horowitz; Julie M Vose; Robert S Negrin; Ginna G Laport
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-10       Impact factor: 5.742

3.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Authors:  Wolfgang Hiddemann; Michael Kneba; Martin Dreyling; Norbert Schmitz; Eva Lengfelder; Rudolf Schmits; Marcel Reiser; Bernd Metzner; Harriet Harder; Susanna Hegewisch-Becker; Thomas Fischer; Martin Kropff; Hans-Edgar Reis; Mathias Freund; Bernhard Wörmann; Roland Fuchs; Manfred Planker; Jörg Schimke; Hartmut Eimermacher; Lorenz Trümper; Ali Aldaoud; Reza Parwaresch; Michael Unterhalt
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up.

Authors:  M Kornacker; J Stumm; C Pott; S Dietrich; S Süssmilch; M Hensel; M Nickelsen; M Witzens-Harig; M Kneba; N Schmitz; A D Ho; P Dreger
Journal:  Ann Oncol       Date:  2009-01-29       Impact factor: 32.976

6.  High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial.

Authors:  Harry C Schouten; Wendi Qian; Stein Kvaloy; Adolfo Porcellini; Hans Hagberg; Hans Erik Johnsen; Jeanette K Doorduijn; Matthew R Sydes; Gunnar Kvalheim
Journal:  J Clin Oncol       Date:  2003-09-29       Impact factor: 44.544

7.  Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.

Authors:  Evgeny Klyuchnikov; Ulrike Bacher; Nicolaus M Kröger; Parameswaran N Hari; Kwang Woo Ahn; Jeanette Carreras; Veronika Bachanova; Asad Bashey; Jonathon B Cohen; Anita D'Souza; César O Freytes; Robert Peter Gale; Siddhartha Ganguly; Mark S Hertzberg; Leona A Holmberg; Mohamed A Kharfan-Dabaja; Andreas Klein; Grace H Ku; Ginna G Laport; Hillard M Lazarus; Alan M Miller; Alberto Mussetti; Richard F Olsson; Shimon Slavin; Saad Z Usmani; Ravi Vij; William A Wood; David G Maloney; Anna M Sureda; Sonali M Smith; Mehdi Hamadani
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-04       Impact factor: 5.742

8.  The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.

Authors:  S P Robinson; C Canals; J J Luang; H Tilly; C Crawley; J Y Cahn; D Pohlreich; S Le Gouill; M Gilleece; N Milpied; M Attal; P Biron; S Maury; A Rambaldi; J Maertens; S Capria; P Colombat; S Montoto; A Sureda
Journal:  Bone Marrow Transplant       Date:  2013-06-17       Impact factor: 5.483

9.  Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Irit Avivi; Silvia Montoto; Carme Canals; John Maertens; Haifa Al-Ali; Ghulam J Mufti; Jürgen Finke; Anton Schattenberg; Renato Fanin; Jan J Cornelissen; Jean-Paul Vernant; Nigell Russell; Yves Beguin; Kirsty Thomson; Leo F Verdonck; Guido Kobbe; Herve Tilly; Gerard Socié; Anna Sureda
Journal:  Br J Haematol       Date:  2009-09-30       Impact factor: 6.998

10.  Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation.

Authors:  Craig S Sauter; Lauren Lechner; Michael Scordo; Junting Zheng; Sean M Devlin; Stephen E Fleming; Hugo Castro-Malaspina; Craig H Moskowitz
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-15       Impact factor: 5.742
View more
  4 in total

Review 1.  Current challenges in the management of follicular lymphoma.

Authors:  Maryam Sarraf Yazdy; Chaitra Ujjani
Journal:  Int J Hematol Oncol       Date:  2017-06-30

Review 2.  Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.

Authors:  Timothy S Fenske; Mehdi Hamadani; Jonathon B Cohen; Luciano J Costa; Brad S Kahl; Andrew M Evens; Paul A Hamlin; Hillard M Lazarus; Effie Petersdorf; Christopher Bredeson
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-27       Impact factor: 5.742

3.  Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.

Authors:  Sonali M Smith; James Godfrey; Kwang Woo Ahn; Alyssa DiGilio; Sairah Ahmed; Vaibhav Agrawal; Veronika Bachanova; Ulrike Bacher; Asad Bashey; Javier Bolaños-Meade; Mitchell Cairo; Andy Chen; Saurabh Chhabra; Edward Copelan; Parastoo B Dahi; Mahmoud Aljurf; Umar Farooq; Siddhartha Ganguly; Mark Hertzberg; Leona Holmberg; David Inwards; Abraham S Kanate; Reem Karmali; Vaishalee P Kenkre; Mohamed A Kharfan-Dabaja; Andreas Klein; Hillard M Lazarus; Matthew Mei; Alberto Mussetti; Taiga Nishihori; Praveen Ramakrishnan Geethakumari; Ayman Saad; Bipin N Savani; Harry C Schouten; Nirav Shah; Alvaro Urbano-Ispizua; Ravi Vij; Julie Vose; Anna Sureda; Mehdi Hamadani
Journal:  Cancer       Date:  2018-04-12       Impact factor: 6.860

4.  Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.

Authors:  Jianhong Wang; Xiaohui Duan; Lijie Yang; Xiangxiang Liu; Caixia Hao; Hongjuan Dong; Hongtao Gu; Hailong Tang; Baoxia Dong; Tao Zhang; Guangxun Gao; Rong Liang
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.